Hangzhou Tigermed Consulting Co., Ltd. (abbrev. “TIGERMED”) disclosed a Next Day Disclosure Return on 17 June 2026, detailing the latest share repurchase executed on the Shenzhen Stock Exchange.

On 17 June 2026, TIGERMED repurchased 833,600 A-shares via on-market transactions at prices ranging from RMB 38.78 to RMB 39.97 per share. The aggregate consideration reached RMB 33.03 million, implying a volume-weighted average cost of roughly RMB 39.62 per share. All repurchased shares are being held as treasury shares.

Following this transaction, the company’s treasury stock increased from 23.67 million to 24.50 million shares. The number of issued shares outstanding (excluding treasury shares) declined from 714.23 million to 713.40 million, a reduction of 0.12%. Total issued share capital remains unchanged at 737.90 million shares, as the repurchased shares have not been cancelled.

The filing affirms that the repurchase complied with both Hong Kong Stock Exchange rules and the relevant Shenzhen Stock Exchange regulations. No additional information regarding the repurchase mandate or future issuance restrictions was provided in the disclosure.